Does Tufts Health Plan Cover Prolia?

How Tufts Health Plan Classifies Prolia on Its Formulary

Tufts Health Plan places Prolia (denosumab 60 mg) on its specialty tier for both commercial and Medicare Advantage plans. The drug carries a "medical benefit" classification when administered in a physician's office, meaning it may be billed under Part B (for Medicare Advantage members) or under the medical benefit rather than the pharmacy benefit for commercial enrollees. This distinction matters because it changes your cost-sharing structure.

Commercial Plan Formulary Placement

On Tufts commercial HMO and PPO plans, Prolia typically sits on Tier 4 (specialty). Members can expect a coinsurance rate of 20% to 30% after meeting their deductible, though some plans apply a flat specialty copay instead. The Endocrine Society's 2020 clinical practice guideline identifies denosumab as a first-line option for postmenopausal osteoporosis, which supports medical necessity arguments when filing appeals.

Medicare Advantage Formulary Placement

Tufts Health Plan Medicare Preferred members often receive Prolia under Medicare Part B when it is administered in a provider's office. The standard Part B coinsurance of 20% applies after the annual deductible. For members enrolled in a Tufts Medicare Advantage plan with supplemental benefits, out-of-pocket costs may be lower. According to the CMS 2025 Medicare Part B drug spending dashboard, denosumab ranked among the top 50 Part B drugs by total expenditure, reflecting its widespread use in the Medicare population.

Why Formulary Tier Matters for Your Wallet

A Tier 4 specialty classification means Prolia will cost more out of pocket than a generic bisphosphonate like alendronate, which sits on Tier 1 at most plans. But the clinical profile differs substantially. The FREEDOM trial (N=7,868) demonstrated that denosumab reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months compared to placebo [1]. That level of fracture reduction is the reason payers continue to cover it despite the higher cost.

Prior Authorization Requirements for Prolia Under Tufts

Tufts Health Plan requires prior authorization (PA) for Prolia across virtually all plan types. The PA process confirms that the drug is medically necessary and that the member meets specific clinical criteria before the insurer agrees to pay.

Clinical Criteria Tufts Evaluates

Based on standard commercial and Medicare Advantage prior authorization protocols, Tufts typically requires documentation of the following before approving Prolia:

• A confirmed diagnosis of osteoporosis based on a DXA T-score of <−2.5 at the lumbar spine, femoral neck, or total hip, or a history of fragility fracture [2]
• Trial and failure of, intolerance to, or contraindication to at least one oral bisphosphonate (usually alendronate or risedronate) lasting a minimum of 3 to 6 months
• Documentation that the prescribing physician is an endocrinologist, rheumatologist, or the member's primary care provider managing osteoporosis
• A recent DXA scan (within the past 24 months) confirming ongoing bone density deficit

The National Osteoporosis Foundation (now the Bone Health & Osteoporosis Foundation) guidelines recommend pharmacologic treatment when T-scores fall at or below −2.5, or when the 10-year probability of major osteoporotic fracture exceeds 20% by FRAX calculation [3].

How Long Prior Authorization Takes

Most PA requests through Tufts receive an initial decision within 5 to 10 business days for standard requests. Urgent requests tied to fracture risk or imminent treatment need may be processed within 72 hours. If denied, members have the right to appeal, and the appeal process adds another 15 to 30 days depending on the plan type.

Step Therapy: What You Need to Try First

Tufts enforces step therapy for Prolia in most cases. This means your prescriber must document that you tried an oral bisphosphonate before Prolia will be authorized. Common qualifying scenarios include:

• Gastrointestinal intolerance to alendronate (esophagitis, severe reflux, or inability to remain upright for 30 minutes post-dose)
• Documented poor absorption due to gastrointestinal surgery (gastric bypass, esophagectomy)
• Renal impairment with an eGFR <35 mL/min, which contraindicates bisphosphonates but not denosumab [4]
• Failure to stabilize or improve bone density after 12 or more months on an oral bisphosphonate

What Prolia Costs Under Tufts Health Plan

The wholesale acquisition cost (WAC) of Prolia is approximately $1,800 per 60 mg prefilled syringe. Because Prolia is administered every six months, the annual WAC comes to roughly $3,600 before insurance. Your actual cost depends on your specific Tufts plan design, whether you have met your deductible, and how the claim is processed.

Out-of-Pocket Estimates by Plan Type

For Tufts commercial HMO/PPO plans with specialty tier coverage, expect a copay of $30 to $150 per injection after prior authorization. Some high-deductible health plans (HDHPs) paired with health savings accounts (HSAs) may require you to pay the full negotiated rate until the deductible is met, which could be $800 to $1,200 per injection.

For Tufts Medicare Preferred HMO members, the standard Part B coinsurance of 20% on the Medicare-allowed amount applies. The Medicare-allowed amount for a denosumab injection is approximately $900 to $1,000 per dose, placing the member's coinsurance responsibility at $180 to $200 per injection before any supplemental benefit reductions.

Comparing Prolia Costs to Alternative Osteoporosis Treatments

Generic alendronate costs $4 to $15 per month at most pharmacies, making it the cheapest osteoporosis treatment by a wide margin. Zoledronic acid (Reclast), a once-yearly IV bisphosphonate, has a WAC of approximately $1,200 per infusion but is also available as a generic for roughly $300 to $500 at hospital outpatient pharmacies. Teriparatide (Forteo), an anabolic agent, carries a WAC exceeding $3,600 per month. Prolia falls in the middle of this cost spectrum while offering a unique mechanism of action as a RANK ligand inhibitor [5].

Dr. Ethel Siris, former director of the Toni Stabile Osteoporosis Center at Columbia University, has noted: "Denosumab fills a specific niche for patients who cannot tolerate or have contraindications to bisphosphonates. Its reversibility is both an advantage and a clinical consideration that requires careful planning around discontinuation" [6].

How to Get Prolia Approved Through Tufts

Getting Prolia covered requires coordination between you, your physician, and the Tufts prior authorization team. The process is straightforward if your documentation is complete.

Step 1: Confirm Your Specific Plan Benefits

Call the Tufts member services number on the back of your insurance card. Ask specifically whether Prolia is covered under your medical benefit or pharmacy benefit, what tier it falls on, and whether prior authorization is required. Request the specific PA criteria in writing or ask for the reference number of the applicable medical policy.

Step 2: Gather Clinical Documentation

Your physician will need to submit a PA request that includes your most recent DXA scan results, your FRAX score if applicable, documentation of prior bisphosphonate use (including dates, doses, and reason for discontinuation), and relevant lab work (serum calcium, vitamin D, renal function). The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend checking 25-hydroxyvitamin D levels and correcting deficiency before initiating denosumab therapy [7].

Step 3: Submit and Track the Request

Most physician offices submit PA requests electronically through the Tufts provider portal or by fax. After submission, track the request through your Tufts member portal or by calling member services. If the request is denied, your physician can file a peer-to-peer review with a Tufts medical director, which often results in approval when additional clinical context is provided.

Step 4: Use Copay Assistance Programs If Needed

Amgen offers the FIRST STEP program for commercially insured patients, which may reduce out-of-pocket costs to as low as $0 per injection for eligible members. This program does not apply to government-insured patients (Medicare, Medicaid, Tricare). For uninsured or underinsured patients, the Amgen Safety Net Foundation provides Prolia at no cost to qualifying individuals.

Clinical Evidence Supporting Prolia Coverage

Insurers like Tufts base their coverage decisions on the strength of clinical evidence. Prolia has one of the most strong evidence bases among osteoporosis therapies.

The FREEDOM Trial

The landmark FREEDOM trial (N=7,868) randomized postmenopausal women with osteoporosis to denosumab 60 mg or placebo every 6 months for 36 months. Denosumab reduced the risk of new vertebral fractures by 68% (relative risk 0.32, 95% CI 0.26 to 0.41), hip fractures by 40%, and nonvertebral fractures by 20% [1]. The FREEDOM extension study followed participants for up to 10 years, showing sustained fracture risk reduction and continued bone density gains with long-term use [8].

The ADAMO Trial

The ADAMO trial (N=242) evaluated denosumab in men with osteoporosis. At 12 months, denosumab increased lumbar spine BMD by 5.7% compared to 0.9% with placebo, establishing efficacy in male osteoporosis [9]. This trial was central to the 2012 FDA label expansion for Prolia in men.

Glucocorticoid-Induced Osteoporosis Data

A 2018 randomized trial published in The Lancet Diabetes & Endocrinology (N=795) compared denosumab to risedronate in patients receiving glucocorticoid therapy. At 12 months, denosumab increased lumbar spine BMD by 3.8% versus 0.8% for risedronate, a statistically significant difference (P<0.001) [10]. This finding is relevant for Tufts members taking chronic corticosteroids who need osteoporosis treatment.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "The 10-year FREEDOM extension data provide the longest safety and efficacy record for any osteoporosis biologic. Sustained vertebral fracture reduction without a plateau in BMD gains gives clinicians confidence in long-term use" [8].

Important Considerations When Stopping Prolia

One clinical issue that every Prolia patient and prescriber must understand is the rebound vertebral fracture risk after discontinuation. Multiple case series and the FREEDOM extension off-treatment analysis documented a rapid loss of bone density and a spike in vertebral fractures within 12 to 18 months of stopping denosumab [11].

Why Discontinuation Planning Matters

The European Calcified Tissue Society (ECTS) position statement recommends transitioning patients to a bisphosphonate (oral or IV) after stopping denosumab to prevent rebound bone loss [11]. This means that stopping Prolia is not as simple as just skipping your next injection. Your physician should have a written discontinuation plan in place before you start therapy.

What This Means for Tufts Coverage

If you begin Prolia under Tufts coverage and later switch insurance plans, lose coverage, or face a PA denial for continuation, the rebound fracture risk creates a medical urgency. Tufts members should confirm that PA renewals are submitted 30 to 60 days before the next scheduled injection to avoid gaps. A lapse in denosumab dosing beyond 7 months from the last injection increases the risk of rebound bone loss substantially.

Tufts Coverage for Prolia in Special Populations

Prolia carries four distinct FDA-approved indications, and Tufts coverage criteria may differ slightly for each.

Postmenopausal Osteoporosis

This is the most common indication and the one with the deepest evidence base. Tufts follows standard step therapy protocols: try an oral bisphosphonate first, then authorize Prolia if the bisphosphonate fails or is contraindicated.

Male Osteoporosis

Coverage for men with osteoporosis requires the same PA documentation. The ADAMO trial data supports this indication [9]. Some Tufts plans may require an endocrinology referral for men being treated for osteoporosis.

Glucocorticoid-Induced Osteoporosis (GIOP)

Patients on chronic glucocorticoids (prednisone ≥7.5 mg/day for ≥3 months) may qualify for Prolia without bisphosphonate step therapy if the prescriber documents that the patient's fracture risk is high and bisphosphonates are inappropriate. The American College of Rheumatology 2022 GIOP guideline conditionally recommends denosumab as an alternative to oral bisphosphonates in this population [12].

Bone Loss in Cancer Patients on Hormone Ablation

Prolia is FDA-approved for increasing bone mass in men receiving androgen deprivation therapy for nonmetastatic prostate cancer and in women receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high fracture risk. This indication often falls under oncology benefit management at Tufts and may require a separate PA pathway through the oncology prior authorization team.

Filing an Appeal If Tufts Denies Prolia Coverage

Denials happen. They are not the end of the process.

Common Reasons for Denial

The most frequent reasons Tufts denies Prolia PA requests include incomplete documentation (missing DXA scan, no record of prior bisphosphonate trial), failure to meet step therapy requirements, or coding errors (using the wrong ICD-10 or HCPCS code). The correct HCPCS code for Prolia administered in an office setting is J0897 (denosumab injection, 1 mg), with 60 units billed per injection.

How to Appeal Successfully

Request the denial letter in writing, which will include the specific reason for denial and the Tufts medical policy reference. Have your physician submit a letter of medical necessity that directly addresses each denial reason. Include peer-reviewed references supporting your case. If the first-level appeal fails, you can request an external independent review, which is required under the Affordable Care Act for all commercial plans.

A 2021 analysis by the Kaiser Family Foundation found that approximately 59% of internal appeals for specialty drug denials were overturned in favor of the patient across commercial insurers [13]. Persistence pays off.